The use of a spironolactone and althiazide combination (aldactacine) in the treatment of benign essential hypertension.
The effects of placebo and of a spironolactone-althiazide combination in the treatment of twenty-two Kenyan Africans with hypertension were assessed using a double-blind technique. After a 2-week medication-free period, patients were randomly allocated to placebo or active treatment for 6 weeks then crossing over to the alternative medication for a further 6 weeks, reverting to the original medication for a final 6 weeks. 100 mg spironolactone plus 60 mg althiazide per day was found to produce greater falls in blood pressure when compared with the placebo periods, sometimes significantly. No serious side-effects were reported. Electrolytes remained within normal limits.
D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010919:Placebos; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013148:Spironolactone / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D010919:Placebos; D049993:Sodium Chloride Symporter Inhibitors; D013449:Sulfonamides; D013148:Spironolactone; C026063:spironolactone, althiazide drug combination